BofA/Merrill Lynch downgraded Theravance Inc. (NASDAQ: THRX) from Buy to Neutral with a price target of $31.00 (from $34.00) as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE